Lioton (Heparin Sodium)

Heparin Sodium is used as an anticoagulant to manage and prevent thrombotic disorders.

• Deep Vein Thrombosis prophylaxis: reduces risk of clot formation in at‑risk patients.
• Pulmonary Embolism prevention: helps avoid embolic events after surgery.
• Superficial thrombophlebitis treatment: alleviates clot formation in superficial veins.
• Vascular graft patency: maintains openness of surgically placed grafts.
• Hemodialysis circuit anticoagulation: prevents clotting in extracorporeal circuits.

• Heparin Sodium potentiates antithrombin III, leading to inhibition of thrombin (factor IIa) and factor Xa activity. By enhancing antithrombin's natural anticoagulant effect, it reduces the conversion of fibrinogen to fibrin, thereby limiting clot formation within the vascular system and at sites of topical application.

Adverse reactions may occur with topical heparin use.

Common Side Effects

• Local skin irritation: mild redness or itching at the application site.
• Redness: transient erythema where the product is applied.
• Minor bruising: small subcutaneous bleedings near the treated area.

Serious or Rare Side Effects

• Severe bleeding: excessive hemorrhage beyond the site of application.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated drop in platelet count.
• Allergic reaction (anaphylaxis): rare systemic hypersensitivity requiring immediate medical attention.

Careful monitoring and appropriate handling are essential when using Lioton.

• Monitor for bleeding: assess wound and systemic signs regularly.
• Check platelet count: periodic monitoring to detect heparin‑induced thrombocytopenia.
• Avoid use on open wounds: apply only to intact skin.
• Use with caution in renal impairment: adjust monitoring as needed.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Heparin Sodium can interact with several other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Concomitant anticoagulants (e.g., warfarin, direct oral anticoagulants): increased risk of severe bleeding.
• Antiplatelet agents (e.g., aspirin, clopidogrel): additive antithrombotic effect.
• Thrombolytic therapy (e.g., alteplase): potentiates hemorrhagic complications.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance bleeding tendency.
• ACE inhibitors: potential for additive hypotensive effects.
• Certain antibiotics (e.g., quinolones): may alter heparin metabolism or platelet function.